Kamada (KMDA)

[midastouch017]

Kamada Ltd gains approval in the prevention of rabies

Kamada Ltd (KMDA) is an Israeli small-cap pharma company developing antitrypsin for various diseases, in partnership with Shire (SHPG). However, this isn't the end of their clinical pipeline. They are also developing an antiviral immunoglobulin directed against the rabies virus in people who have been exposed.

KMDA announced recently that they've received approval from the FDA to market their anti-rabies immunoglobulin, based on findings supporting non-inferiority against immunoglobulin G reference. KMDA's product did not negatively impact the formation of neutralizing antibodies upon administration of rabies vaccine.

Looking forward: This isn't the first such anti-rabies immunoglobulin product to be marketed in the United States. However, KMDA has been keen to point out that the supply of these therapies has been unstable. Immediate prophylaxis with anti-rabies immunoglobulin remains a key first step toward getting the viral load under control and preventing a fatal infection until the vaccine gets to work. And with that KMDA gets its second drug approval in the US!

https://seekingalpha.com/article/4102162-3-things-biotech-learn-today-august-27-2017?ifp=0&app=1